The creation of Arrotex marks the emergence of a new central player in the Australian generics market, born as a result of the merger between Apotex’ local business and former Strides unit Arrow Pharmaceuticals which closed on 10 July.
Newly-Formed Arrotex Is Considering Further Deals
Following the formation of Australia’s Arrotex through the merger of Apotex Australia and former Strides unit Arrow Pharmaceuticals, CEO Dennis Bastas sets out the firm’s priorities as a central player in the Australian market, as well as longer-term plans including potential future deals and reaching beyond Australia and into south-east Asia, in an exclusive interview with Generics Bulletin.
